SynthesisWorld journal of gastroenterology2014
Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy.
Synthesis in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses.Scientific reports · 2024Pooled it
- Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment ofThe Journal of international medical research · 2023Pooled it
- Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis.Medicine · 2019Pooled it
- Probiotic monotherapy andWorld journal of gastroenterology · 2018Pooled it
- Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2015Pooled it
- Review
- Washed microbiota transplantation is associated withFrontiers in medicine · 2026Article
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers.Journal of gastrointestinal cancer · 2024Review
- Influence of tumor mycobiome on cancer pathogenesis (Review).Oncology letters · 2023Review
- The Influence ofAntibiotics (Basel, Switzerland) · 2023Review
- Helicobacter pylori treatment knowledge, access and barriers: A cross-sectional study.Helicobacter · 2023Article
- Traditional and Modern Diagnostic Approaches in Diagnosing PediatricChildren (Basel, Switzerland) · 2022Review
- Evolution of Diagnostic Methods forDiagnostics (Basel, Switzerland) · 2022Review
- Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections.BMC gastroenterology · 2021Article
- Article
- Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- The Bacterial Microbiota of Gastrointestinal Cancers: Role in Cancer Pathogenesis and Therapeutic Perspectives.Clinical and experimental gastroenterology · 2020Review
- Detection of gastritis by a deep convolutional neural network from double-contrast upper gastrointestinal barium X-ray radiography.Journal of gastroenterology · 2019Article
- Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy forMiddle East journal of digestive diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the role of probiotics in the standard triple Helicobacter pylori therapy.
methodsIn this meta-analysis, we investigated the efficacy of probiotics in a standard triple H. pylori therapy in adults. Searches were mainly conducted in MEDLINE/PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Fourteen studies met our criteria, and the quality of these studies was assessed using the Jadad scale. We used STATA version 12.0 to extract data and to calculate the odds ratios (ORs), which are presented with the corresponding 95% confidence intervals (CIs). The data are presented as forest plots.
resultsThe pooled ORs for the eradication rates calculated by intention-to-treat analysis and per-protocol analysis in the probiotic group vs the control group were 1.67 (95%CI: 1.38-2.02) and 1.68 (95%CI: 1.35-2.08), respectively, using the fixed-effects model. The sensitivity of the Asian studies was greater than that of the Caucasian studies (Asian: OR = 1.78, 95%CI: 1.40-2.26; Caucasian: OR = 1.48, 95%CI: 1.06-2.05). The pooled OR for the incidence of total adverse effects was significantly lower in the probiotic group (OR = 0.49, 95%CI: 0.26-0.94), using the random effects model, with significant heterogeneity (I (2) = 85.7%). The incidence of diarrhea was significantly reduced in the probiotic group (OR = 0.21, 95%CI: 0.06-0.74), whereas the incidence of taste disorders, metallic taste, vomiting, nausea, and epigastric pain did not differ significantly between the probiotic group and the control group.
conclusionSupplementary probiotic preparations during standard triple H. pylori therapy may improve the eradication rate, particularly in Asian patients, and the incidence of total adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.